You are not logged in.

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

Khasraw, Mustafa, Lee, Adrian, McCowatt, Sally, Kerestes, Zoltan, Buyse, Marc E., Back, Michael, Kichenadasse, Ganessan, Ackland, Stephen and Wheeler, Helen 2016, Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial, Journal of neuro-oncology, vol. 128, no. 1, pp. 163-171, doi: 10.1007/s11060-016-2094-0.

Attached Files
Name Description MIMEType Size Downloads

Title Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial
Author(s) Khasraw, MustafaORCID iD for Khasraw, Mustafa orcid.org/0000-0003-3249-9849
Lee, Adrian
McCowatt, Sally
Kerestes, Zoltan
Buyse, Marc E.
Back, Michael
Kichenadasse, Ganessan
Ackland, Stephen
Wheeler, Helen
Journal name Journal of neuro-oncology
Volume number 128
Issue number 1
Start page 163
End page 171
Total pages 9
Publisher Springer
Place of publication New York, N.Y.
Publication date 2016-05
ISSN 0167-594X
1573-7373
Summary Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12 months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients. Eligible patients (newly diagnosed, histologically confirmed supratentorial glioblastoma with unmethylated MGMT promoter) were entered into this multicentre study. Cilengitide (2000 mg IV twice weekly) was commenced 1 week prior to radiotherapy combined with daily temozolomide (60 mg/m2) and procarbazine (50 or 100 mg) and, after 4 weeks’ break, followed by six adjuvant cycles of temozolomide (50–60 mg/m2) and procarbazine (50 or 100 mg) on days 1–20, every 28 days. Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity. The primary endpoint for efficacy was a 12-month overall survival rate of 65 %. Twenty-nine patients completed study treatment. Sixteen patients survived for 12 months or more, an overall survival rate of 55 %. The median overall survival was 14.5 months (95 % CI 11.1–19.6) and the median progression-free survival was 7.4 months (95 % CI 6.1–8). Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation.
Language eng
DOI 10.1007/s11060-016-2094-0
Field of Research 111208 Radiation Therapy
1109 Neurosciences
1112 Oncology And Carcinogenesis
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Springer Science+Business Media New York
Persistent URL http://hdl.handle.net/10536/DRO/DU:30082460

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 4 times in TR Web of Science
Scopus Citation Count Cited 5 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 42 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Thu, 24 Mar 2016, 21:12:07 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.